Common diabetes drug tested against rare, aggressive childhood brain cancer
NCT ID NCT07226453
Summary
This study is testing if metformin, a common diabetes medication, can help control a rare and aggressive brain tumor called PFA ependymoma in children and young adults whose cancer has returned or worsened after standard treatment. The two-part study first checks if the drug affects specific markers in the tumor cells, then measures if it can stabilize the disease. It aims to enroll 30 participants aged 1 to 39 years who have already had surgery and radiation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTERIOR FOSSA EPENDYMAL TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.